October 12, 2011

HELIX BIOPHARMA CORP. FILES IND CLINICAL HOLD RESPONSE WITH FDA FOR ITS PLANNED TOPICAL INTERFERON ALPHA-2B PHASE II/III EFFICACY TRIAL (PDF)

AURORA, Ontario, October 12, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical
company developing drug candidates for the prevention and treatment of cancer, today announced that it has filed its complete response to the “clinical hold” issues previously raised by the United States Food and Drug Administration (“FDA”) related to its pending Topical Interferon Alpha-2b, Phase II/III, low-grade cervical lesion efficacy trial investigational new drug (“IND”) application. Topical Interferon Alpha-2b is the Company’s most advanced product in development incorporating its proprietary Biphasix™ drug delivery technology and is designed to offer a superior means of delivering interferon-alpha-2b therapeutically to human papillomavirus (HPV) infected tissues.